{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:29:02Z","timestamp":1792801742330,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018502","name":"Kanazawa University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018502","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kameda Medical Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In this study, the minimal residual disease (MRD) levels in patients with multiple myeloma (MM) were assessed by comparing the new 8-color single-tube multiparameter flow cytometry method (DuraClone), which reduces the cost of antibodies and labor burden of laboratories, with the EuroFlow next-generation flow (NGF) method. A total of 96 samples derived from 69 patients with MM were assessed to determine the total cell acquisition number (tCAN), percentages of total and normal plasma cells (PCs), and MRD levels using two methods. We found that the tCAN was significantly higher with EuroFlow-NGF than with DuraClone (median 8.6\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    vs. 5.7\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    ;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). In addition, a significant correlation in the MRD levels between the two methods was noted (r\u2009=\u20090.92,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). However, in the qualitative analysis, 5.2% (5\/96) of the samples showed discrepancies in the MRD levels. In conclusion, the DuraClone is a good option to evaluate MRD in multiple myeloma but it should be used with caution.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-89761-9","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T06:16:36Z","timestamp":1622096196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods"],"prefix":"10.1038","volume":"11","author":[{"given":"Takeshi","family":"Yoroidaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"issue":"4","key":"89761_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/joim.12590","volume":"281","author":"O Landgren","year":"2017","unstructured":"Landgren, O. & Iskander, K. Modern multiple myeloma therapy: Deep, sustained treatment response and good clinical outcomes. J. Intern. Med. 281(4), 365\u2013382. https:\/\/doi.org\/10.1111\/joim.12590 (2017).","journal-title":"J. Intern. Med."},{"key":"89761_CR2","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1038\/bcj.2015.79","volume":"5","author":"S Ozaki","year":"2015","unstructured":"Ozaki, S. et al. Trends of survival in patients with multiple myeloma in Japan: A multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 5, e349. https:\/\/doi.org\/10.1038\/bcj.2015.79 (2015).","journal-title":"Blood Cancer J."},{"issue":"10218","key":"89761_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial. Lancet 395(10218), 132\u2013141. https:\/\/doi.org\/10.1016\/S0140-6736(19)32956-3 (2020).","journal-title":"Lancet"},{"issue":"22","key":"89761_CR4","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl. J. Med. 380(22), 2104\u20132115. https:\/\/doi.org\/10.1056\/NEJMoa1817249 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"89761_CR5","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","volume":"123","author":"J Martinez-Lopez","year":"2014","unstructured":"Martinez-Lopez, J. et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123(20), 3073\u20133079. https:\/\/doi.org\/10.1182\/blood-2014-01-550020 (2014).","journal-title":"Blood"},{"issue":"10","key":"89761_CR6","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1093\/annonc\/mdx340","volume":"28","author":"H Takamatsu","year":"2017","unstructured":"Takamatsu, H. et al. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Ann. Oncol. 28(10), 2503\u20132510. https:\/\/doi.org\/10.1093\/annonc\/mdx340 (2017).","journal-title":"Ann. Oncol."},{"issue":"12","key":"89761_CR7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/bmt.2016.222","volume":"51","author":"O Landgren","year":"2016","unstructured":"Landgren, O., Devlin, S., Boulad, M. & Mailankody, S. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: A meta-analysis. Bone Marrow Transplant. 51(12), 1565\u20131568. https:\/\/doi.org\/10.1038\/bmt.2016.222 (2016).","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"89761_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi, N. C. et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis. JAMA Oncol. 3(1), 28\u201335. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3160 (2017).","journal-title":"JAMA Oncol."},{"issue":"23","key":"89761_CR9","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132(23), 2456\u20132464. https:\/\/doi.org\/10.1182\/blood-2018-06-858613 (2018).","journal-title":"Blood"},{"issue":"8","key":"89761_CR10","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17(8), e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6 (2016).","journal-title":"Lancet Oncol."},{"issue":"10","key":"89761_CR11","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero, J. et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31(10), 2094\u20132103. https:\/\/doi.org\/10.1038\/leu.2017.29 (2017).","journal-title":"Leukemia"},{"issue":"20","key":"89761_CR12","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva, B., van Dongen, J. J. & Orfao, A. New criteria for response assessment: Role of minimal residual disease in multiple myeloma. Blood 125(20), 3059\u20133068. https:\/\/doi.org\/10.1182\/blood-2014-11-568907 (2015).","journal-title":"Blood"},{"issue":"11","key":"89761_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/jcm6110106","volume":"6","author":"H Takamatsu","year":"2017","unstructured":"Takamatsu, H. Comparison of minimal residual disease detection by multiparameter flow cytometry, ASO-qPCR, Droplet digital PCR, and deep sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. J. Clin. Med. 6(11), 91. https:\/\/doi.org\/10.3390\/jcm6110106 (2017).","journal-title":"J. Clin. Med."},{"issue":"4","key":"89761_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12185-019-02615-z","volume":"109","author":"H Takamatsu","year":"2019","unstructured":"Takamatsu, H. et al. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int. J. Hematol. 109(4), 377\u2013381. https:\/\/doi.org\/10.1007\/s12185-019-02615-z (2019).","journal-title":"Int. J. Hematol."},{"issue":"1","key":"89761_CR15","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1038\/s41598-019-39631-2","volume":"9","author":"A Blum","year":"2019","unstructured":"Blum, A. et al. Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma. Sci. Rep. 9(1), 2922. https:\/\/doi.org\/10.1038\/s41598-019-39631-2 (2019).","journal-title":"Sci. Rep."},{"issue":"3","key":"89761_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.11080","volume":"93","author":"AC Rawstron","year":"2008","unstructured":"Rawstron, A. C. et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 93(3), 431\u2013438. https:\/\/doi.org\/10.3324\/haematol.11080 (2008).","journal-title":"Haematologica"},{"issue":"3","key":"89761_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48(3), 452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244 (2013).","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"89761_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/cyto.b.21228","volume":"90","author":"M Arroz","year":"2016","unstructured":"Arroz, M. et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin. Cytom. 90(1), 31\u201339. https:\/\/doi.org\/10.1002\/cyto.b.21228 (2016).","journal-title":"Cytometry B Clin. Cytom."},{"issue":"1","key":"89761_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cyto.b.21249","volume":"90","author":"M Stetler-Stevenson","year":"2016","unstructured":"Stetler-Stevenson, M. et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin. Cytom. 90(1), 26\u201330. https:\/\/doi.org\/10.1002\/cyto.b.21249 (2016).","journal-title":"Cytometry B Clin. Cytom."},{"issue":"12","key":"89761_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","volume":"1","author":"M Roshal","year":"2017","unstructured":"Roshal, M. et al. MRD detection in multiple myeloma: Comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Adv. 1(12), 728\u2013732. https:\/\/doi.org\/10.1182\/bloodadvances.2016003715 (2017).","journal-title":"Blood Adv."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89761-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89761-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89761-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:59:57Z","timestamp":1670039997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89761-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89761"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89761-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"9 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HT received honoraria from Janssen, Bristol-Myers Squibb and Adaptive Biotechnologies; research funds from Janssen, Bristol-Myers Squibb, Ono Pharmaceutical and SRL. SN received an advisory fee from SymBio Pharmaceuticals; honoraria from Novartis and Kyowa Kirin; a research fund from Alexion Pharmaceuticals. KM received honoraria from Janssen, Bristol-Myers Squibb and Takeda. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11218"}}